

Michigan Pharmacy and Therapeutics Committee
Diabetes Workgroup
August 2009

Following review and discussion, the workgroup recommends to the full Committee the following for the review of the diabetes drug classes on the Preferred Drug List:

Amylin Analogs: no change to current classification

Secretin Mimetics: no change to current classification

Insulins, Basal: no change to current classification

Insulins, Rapid Acting: no change to current classification

Insulin Mixes: no change to current classification

Insulins, Traditional: no change to current classification

Oral Hypoglycemics-Alpha Glucosidase Inh.: no change to current classification

Oral Hypoglycemics-Biguanides: no change to current classification

Oral Hypoglycemics-Combinations: no change to current classification

Oral Hypoglycemics-DPP4 Inhibitors: no change to current classification

Oral Hypoglycemics-Meglitinides: no change to current classification

Oral Hypoglycemics-2nd Gen Sulfonylureas: no change to current classification

Oral Hypoglycemics-Thiazolidinediones: no change to current classification